• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.多中心弥漫性低级别胶质瘤的起源和演化的基因组分析。
Neuro Oncol. 2018 Apr 9;20(5):632-641. doi: 10.1093/neuonc/nox205.
2
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.采用全基因组和转录组谱分析对弥漫性脑 WHO 分级 II/III 级神经胶质瘤进行分子分类,可改善预后不同的患者亚组的分层。
Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18.
3
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.IDH1-R132H 通过表观遗传地上调 DNA 损伤反应在神经胶质瘤中作为肿瘤抑制因子发挥作用。
Sci Transl Med. 2019 Feb 13;11(479). doi: 10.1126/scitranslmed.aaq1427.
4
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.在日本的胶质瘤患者中,IDH 突变的意义随肿瘤组织学、分级和遗传学而异。
Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.
5
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.TERT 启动子突变与 1p/19q 状态无关,对 IDH1/2 突变的成人弥漫性胶质瘤具有有利的预后。
Acta Neuropathol Commun. 2020 Nov 23;8(1):201. doi: 10.1186/s40478-020-01078-2.
6
IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.IDH 突变型弥漫性神经胶质瘤:基因组肿瘤分类时代的技巧与窍门。
Histol Histopathol. 2023 Jul;38(7):739-753. doi: 10.14670/HH-18-582. Epub 2023 Jan 9.
7
Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.形态学、遗传学和空间上混合的星形细胞瘤和少突胶质细胞瘤;1p/19q共缺失和CDKN2A缺失的时间顺序获得:一例报告
Brain Tumor Pathol. 2023 Jan;40(1):26-34. doi: 10.1007/s10014-022-00448-z. Epub 2022 Dec 26.
8
Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.资源受限环境下神经胶质瘤病理评估的诊断算法
J Cancer Res Ther. 2023 Apr-Jun;19(3):562-566. doi: 10.4103/jcrt.jcrt_102_21.
9
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.全外显子组测序确定ATRX突变是低级别胶质瘤的关键分子决定因素。
Oncotarget. 2012 Oct;3(10):1194-203. doi: 10.18632/oncotarget.689.
10
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.弥漫性低级别胶质瘤中遗传改变的预后相关性。
Neuro Oncol. 2018 Jan 10;20(1):66-77. doi: 10.1093/neuonc/nox132.

引用本文的文献

1
Prognostic value of the pre-treatment albumin-to-alkaline phosphatase ratio in patients with lower-grade glioma: a propensity score matching study.低级别胶质瘤患者治疗前白蛋白与碱性磷酸酶比值的预后价值:一项倾向评分匹配研究
Front Pharmacol. 2025 Jul 16;16:1556108. doi: 10.3389/fphar.2025.1556108. eCollection 2025.
2
The prognostic significance of the NMD core factor UPF1 in low-grade glioma.NMD核心因子UPF1在低级别胶质瘤中的预后意义
Sci Rep. 2025 Jul 1;15(1):20574. doi: 10.1038/s41598-025-05711-9.
3
Bioinformatics insights into ACSL1 and ACSL5: prognostic and immune roles in low-grade glioma.ACSL1和ACSL5的生物信息学见解:在低级别胶质瘤中的预后和免疫作用
BMC Cancer. 2025 Feb 10;25(1):226. doi: 10.1186/s12885-025-13651-w.
4
Integrative multi-omics analysis unveils the connection between transcriptomic characteristics associated with mitochondria and the tumor immune microenvironment in lower-grade gliomas.整合多组学分析揭示了与线粒体相关的转录组特征与低级别脑胶质瘤肿瘤免疫微环境之间的联系。
Sci Rep. 2024 Oct 10;14(1):23675. doi: 10.1038/s41598-024-74281-z.
5
Development and validation of a glioma prognostic model based on telomere-related genes and immune infiltration analysis.基于端粒相关基因和免疫浸润分析的胶质瘤预后模型的构建与验证
Transl Cancer Res. 2024 Jul 31;13(7):3182-3199. doi: 10.21037/tcr-23-2294. Epub 2024 Jul 22.
6
Analysis of glutathione Stransferase mu class 5 gene methylation as a prognostic indicator in low-grade gliomas.分析谷胱甘肽 S-转移酶 mu 类 5 基因甲基化为低级别胶质瘤的预后指标。
Technol Health Care. 2024;32(6):3925-3942. doi: 10.3233/THC-231316.
7
STAT3 drives the malignant progression of low-grade gliomas through modulating the expression of STAT1, FOXO1, and MYC.信号转导和转录激活因子3(STAT3)通过调节信号转导和转录激活因子1(STAT1)、叉头框蛋白O1(FOXO1)和原癌基因Myc(MYC)的表达来驱动低级别胶质瘤的恶性进展。
Front Mol Biosci. 2024 Jun 14;11:1419072. doi: 10.3389/fmolb.2024.1419072. eCollection 2024.
8
Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification study.基于线粒体 RNA 修饰的signature 预测低级别胶质瘤的预后:一项多组学探索和验证研究。
Sci Rep. 2024 Jun 1;14(1):12602. doi: 10.1038/s41598-024-63592-w.
9
Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.林奇综合征背景下出现的异柠檬酸脱氢酶突变型和野生型成分具有空间分布特征的错配修复缺陷型胶质瘤。
Cold Spring Harb Mol Case Stud. 2023 May 9;9(2). doi: 10.1101/mcs.a006280. Print 2023 Apr.
10
Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG).ITGB2 表达与脑胶质瘤临床特征的相关性及其在低级别胶质瘤(LGG)中甲基化的预后意义。
Front Endocrinol (Lausanne). 2023 Jan 13;13:1106120. doi: 10.3389/fendo.2022.1106120. eCollection 2022.

本文引用的文献

1
Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?双基因型弥漫性低级别胶质瘤:真的是时候摒弃少突星形细胞瘤这一独立实体了吗?
J Neuropathol Exp Neurol. 2017 May 1;76(5):342-346. doi: 10.1093/jnen/nlx024.
2
Spatiotemporal genomic architecture informs precision oncology in glioblastoma.时空基因组结构为胶质母细胞瘤的精准肿瘤学提供信息。
Nat Genet. 2017 Apr;49(4):594-599. doi: 10.1038/ng.3806. Epub 2017 Mar 6.
3
COSMIC: somatic cancer genetics at high-resolution.COSMIC:高分辨率体细胞癌遗传学
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783. doi: 10.1093/nar/gkw1121. Epub 2016 Nov 28.
4
Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.多中心胶质瘤通过独立于突变型异柠檬酸脱氢酶1的途径发展:多中心胶质瘤的免疫组织化学研究
Pathobiology. 2017;84(2):99-107. doi: 10.1159/000447951. Epub 2016 Aug 24.
5
A case of multicentric gliomas in both supra- and infratentorial regions with different histology: a case report.一例幕上和幕下区域具有不同组织学类型的多中心胶质瘤病例报告
World J Surg Oncol. 2016 May 26;14(1):152. doi: 10.1186/s12957-016-0907-4.
6
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类:概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
7
Understanding inherited genetic risk of adult glioma - a review.了解成人胶质瘤的遗传风险——综述
Neurooncol Pract. 2016 Mar;3(1):10-16. doi: 10.1093/nop/npv026. Epub 2015 Aug 25.
8
Magnetic resonance analysis of malignant transformation in recurrent glioma.复发性胶质瘤恶性转化的磁共振分析
Neuro Oncol. 2016 Aug;18(8):1169-79. doi: 10.1093/neuonc/now008. Epub 2016 Feb 23.
9
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.分子分析揭示弥漫性胶质瘤的生物学离散亚群和进展途径。
Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028.
10
DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors.DNA甲基化与体细胞突变在细胞周期上趋同,并界定了脑肿瘤中相似的进化史。
Cancer Cell. 2015 Sep 14;28(3):307-317. doi: 10.1016/j.ccell.2015.07.012.

多中心弥漫性低级别胶质瘤的起源和演化的基因组分析。

Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

机构信息

Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.

Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA.

出版信息

Neuro Oncol. 2018 Apr 9;20(5):632-641. doi: 10.1093/neuonc/nox205.

DOI:10.1093/neuonc/nox205
PMID:29077933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5892142/
Abstract

BACKGROUND

Rare multicentric lower-grade gliomas (LGGs) represent a unique opportunity to study the heterogeneity among distinct tumor foci in a single patient and to infer their origins and parallel patterns of evolution.

METHODS

In this study, we integrate clinical features, histology, and immunohistochemistry for 4 patients with multicentric LGG, arising both synchronously and metachronously. For 3 patients we analyze the phylogeny of the lesions using exome sequencing, including one case with a total of 8 samples from the 2 lesions.

RESULTS

One patient was diagnosed with multicentric isocitrate dehydrogenase 1 (IDH1) mutated diffuse astrocytomas harboring distinct IDH1 mutations, R132H and R132C; the latter mutation has been associated with Li-Fraumeni syndrome, which was subsequently confirmed in the patient's germline DNA and shown in additional cases with The Cancer Genome Atlas data. In another patient, phylogenetic analysis of synchronously arising grade II and grade III diffuse astrocytomas demonstrated a single shared mutation, IDH1 R132H, and revealed convergent evolution via non-overlapping mutations in ATRX and TP53. In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second.

CONCLUSIONS

Each tumor in multicentric LGG cases may arise independently or may diverge very early in their development, presenting as genetically and histologically distinct tumors. Comprehensive sampling of these lesions can therefore significantly alter diagnosis and management. Additionally, somatic IDH1 R132C mutation in either multicentric or solitary LGG identifies unsuspected germline TP53 mutation, validating the limited number of published cases.

摘要

背景

罕见的多中心低级别胶质瘤(LGG)代表了一个独特的机会,可以研究单个患者中不同肿瘤灶之间的异质性,并推断它们的起源和并行进化模式。

方法

在这项研究中,我们整合了 4 名多中心 LGG 患者的临床特征、组织学和免疫组织化学,这些患者的肿瘤同时或先后发生。对于 3 名患者,我们使用外显子组测序分析病变的系统发育,其中 1 名患者共有 2 个病灶的 8 个样本。

结果

1 名患者被诊断为多中心 IDH1 突变弥漫性星形细胞瘤,具有不同的 IDH1 突变,R132H 和 R132C;后者突变与 Li-Fraumeni 综合征有关,随后在患者的种系 DNA 中得到证实,并在具有癌症基因组图谱数据的其他病例中得到证实。在另 1 名患者中,同步发生的 2 级和 3 级弥漫性星形细胞瘤的系统发育分析显示了 1 个共同的突变 IDH1 R132H,并通过 ATRX 和 TP53 的非重叠突变揭示了趋同进化。在 2 例病例中,IDH1 突变和 1p/19q 缺失的少突胶质细胞瘤和 IDH1 突变和 1p/19q 完整的弥漫性星形细胞瘤发生了分歧进化,1 例同步发生,另 1 例先后发生。

结论

多中心 LGG 病例中的每个肿瘤可能独立发生,也可能在其发育早期就发生分歧,表现为遗传和组织学上明显不同的肿瘤。因此,对这些病变进行全面采样可以显著改变诊断和治疗。此外,多中心或孤立性 LGG 中的体细胞 IDH1 R132C 突变可识别出未被怀疑的种系 TP53 突变,验证了少数已发表的病例。